ID3 and non-small cell lung carcinoma: Additionally, YTHDC2 inhibited drug resistance in non-small cell lung cancer (NSCLC) by upregulating the expression of the tumor suppressor gene Inhibitor of DNA-binding 3 (ID3) in cisplatin-resistant NSCLC cell lines [43].